IDWeek 2022 Poster #P2036

# D al VIM-Prod cing *Proteus mirabilis*, Incl ding a No el VIM-75, Among Elderl Patient in a Medical Center from H ngar : Report from the 2020 SENTRY Antimicrobial S r eillance Program

Lalitaga ri M. De hpande[1], Katalin B rian[2], Ilona D c i C an i[2], Mariana Ca tanheira[1]
[1] JMI Laboratories, North Liberty, IA, USA; [2] Albert Szent-Györgyi Medical Centre, Szeged, Hungary

## Materials and Methods

- A total of 16 . isolates were received from Hungary during 2020 as part of the SENTRY Antimicrobial Surveillance Program.
- Isolates were susceptibility tested by reference broth microdilution as described by the Clinical and Laboratory Standards Institute (CLSI) M07 (2018) and M100 (2022) documents.
  - Quality control (QC) was performed according to the CLSI M100 (2022) criteria.
- Carbapenem-nonsusceptible isolates were submitted to whole genome sequencing and analysis.
  - Total genomic DNA was used as input material for library

Mariana Castanheira
Chief Scientific Officer, JMI Laboratories
345 Beaver Kreek Center, Suite A
North Liberty, Iowa 52317 USA
mariana-castanheira@jmilabs.com

To obtain a PDF of this poster:
Scan the QR code or visit https://www.jmilabs.com/data/posters/IDWeek2022_DualVIM.pdf
No personal information is stored.